Patients n | Univariate# | Multivariate¶ | |||
HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Treatment arm | |||||
Doublet chemotherapy | 148 | 0.81 (0.64–1.03) | 0.0897 | ||
Monotherapy | 144 | 1 | |||
Sex | |||||
Male | 210 | 1 | |||
Female | 82 | 0.67 (0.51–0.88) | 0.004 | ||
Age years | |||||
≤80 | 217 | 0.92 (0.70–1.20) | 0.530 | ||
>80 | 75 | 1 | |||
Performance status | |||||
0–1 | 234 | 0.56 (0.42–0.76) | 0.0002 | 0.63 (0.47–0.86) | 0.0034 |
2 | 58 | 1 | 1 | ||
Stage | |||||
IIIA–IIIB | 47 | 0.82 (0.59–1.13) | 0.218 | ||
IV | 245 | 1 | |||
Histology | |||||
Squamous or other | 142 | 1 | 1 | ||
Adenocarcinoma | 150 | 0.53 (0.42–0.68) | <0.0001 | 0.68 (0.52–0.88) | 0.0039 |
Smoking status | |||||
Never smoked | 68 | 0.50 (0.37–0.67) | <0.0001 | 0.62 (0.45–0.85) | 0.0034 |
Ever smoked | 224 | 1 | 1 | ||
MMS examination | |||||
≤23 | 34 | 1 | |||
>23 | 250 | 0.91 (0.63–1.31) | 0.598 | ||
ADL score | |||||
<6 | 42 | 1 | |||
6 | 239 | 0.82 (0.59–1.15) | 0.252 | ||
CCI | |||||
≤2 | 226 | 0.79 (0.59–1.05) | 0.099 | ||
>2 | 66 | 1 | |||
BMI kg·m−2 | |||||
≤20 | 32 | 1 | |||
20 to ≤26 | 156 | 0.91 (0.62–1.35) | 0.651 | ||
>26 to ≤30 | 70 | 0.75 (0.49–1.15) | 0.180 | ||
>30 | 34 | 0.88 (0.53–1.45) | 0.606 | ||
Weight loss before randomisation % | |||||
≤5 | 144 | 0.66 (0.52–0.84) | 0.0008 | 0.76 (0.60–0.98) | 0.0337 |
>5 | 144 | 1 | 1 |
HR: hazard ratio; MMS: mini-mental state; ADL: activities of daily living questionnaire; CCI: Charlson’s comorbidity index; BMI: body mass index. #: n=292; ¶: n=288.